Hersmus, R. (Remko), Stoop, J.A. (Hans), Geijn, G.J.M. (Gert-Jan) van de, Eini, R. (Ronak), Biermann, K. (Katharina), Oosterhuis, J.W. (Wolter), DHooge, C. (Catharina), Schneider, D.T. (Dominik), Meijssen, I.C. (Isabelle), Dinjens, W.N.M. (Winand), Dubbink, H.J. (Erik Jan), Drop, S.L.S. (Stenvert), Looijenga, L.H.J. (Leendert), Hersmus, R. (Remko), Stoop, J.A. (Hans), Geijn, G.J.M. (Gert-Jan) van de, Eini, R. (Ronak), Biermann, K. (Katharina), Oosterhuis, J.W. (Wolter), DHooge, C. (Catharina), Schneider, D.T. (Dominik), Meijssen, I.C. (Isabelle), Dinjens, W.N.M. (Winand), Dubbink, H.J. (Erik Jan), Drop, S.L.S. (Stenvert), and Looijenga, L.H.J. (Leendert)
Activating c-KIT mutations (exons 11 and 17) are found in 10-40% of testicular seminomas, the majority being missense point mutations (codon 816). Malignant ovarian dysgerminomas represent ~3% of all ovarian cancers in Western countries, resembling testicular seminomas, regarding chromosomal aberrations and c-KIT mutations. DSD patients with specific Y-sequences have an increased risk for Type II Germ Cell Tumor/Cancer, with gonadoblastoma as precursor progressing to dysgerminoma. Here we present analysis of c-KIT exon 8, 9, 11, 13 and 17, and PDGFRA exon 12, 14 and 18 by conventional sequencing together with mutational analysis of c-KIT codon 816 by a sensitive and specific LightCycler melting curve analysis, confirmed by sequencing. The results are combined with data on TSPY and OCT3/4 expression in a series of 16 DSD patients presenting with gonadoblastoma and dysgerminoma and 15 patients presenting pure ovarian dysgerminomas without DSD. c-KIT codon 816 mutations were detected in five out of the total of 31 cases (all found in pure ovarian dysgerminomas). A synonymous SNP (rs 5578615) was detected in two patients, one DSD patient (with bilateral disease) and one patient with dysgerminoma. Next to these, three codon N822K mutations were detected in the group of 15 pure ovarian dysgerminomas. In total activating c-KIT mutations were found in 53% of ovarian dysgerminomas without DSD. In the group of 16 DSD cases a N505I and D820E mutation was found in a single tumor of a patient with gonadoblastoma and dysgerminoma. No PDGFRA mutations were found. Positive OCT3/4 staining was present in all gonadoblastomas and dysgerminomas investigated, TSPY expression was only seen in the gonadoblastoma/dysgerminoma lesions of the 16 DSD patients. This data supports the existence of two distinct but parallel pathways in the development of dysgerminoma, in which mutational status of c-KIT might parallel the presence of TSPY.